EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of drug regimens containing omadacycline in a murine model of Mycobacterium avium chronic lung infection

Jean-Philippe Lanoix, Antoine Froment, Julia Delomez, Jessica V Pierce, Alisa W Serio, Morgane Choquet, Marie Perret, François Peltier, Cédric Joseph, Denis Chatelain, Claire Andréjak

Frontiers in Microbiology · 29.05.2026 · 17

DOI: 10.3389/fmicb.2026.1821617 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 29.05.2026. Verfasst von Jean-Philippe Lanoix und 10 weiteren Autor:innen. Beteiligte Einrichtung: AGIR EA4294, Université de Picardie Jules Verne, Amiens, France. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycobacterium avium complex (MAC) is the most common non-tuberculous mycobacteria (NTM) and most frequent causative pathogen of NTM pulmonary infections. MAC is often associated with comorbidities, chronic infections, and high mortality rates. New treatment options are needed to increase treatment efficacy and tolerance. Omadacycline is a semisynthetic tetracycline-class drug with broad-spectrum activity, including against MAC in vitro . In an aerosol infection model of MAC pulmonary disease, we evaluated 9 treatment regimens that included omadacycline (OMC) alone or in dual, triple, or quadruple combinations with existing antibiotics: rifampin (RIF), clofazimine (CFZ), ethambutol (EMB), and clarithromycin (CLR). Treatment efficacy was assessed based on reduction of bacterial load in the lung and spleen over 4 months. OMC alone and OMC-RIF-EMB groups demonstrated efficacy starting at 2 months of treatment with a final reduction in bacterial burden in the lung of ~1 log 10 and >4 log 10 , respectively, compared with untreated mice. Omadacycline was as efficacious as rifampin in the standard-of-care regimen (CLR-RIF-EMB) over the first 3 months. The most potent combination tested in this study was OMC-CLR-CFZ, with a >5 log 10 reduction of bacterial burden in the lung. This is the first study demonstrating omadacycline efficacy against M. avium in mice alone and as part of a combination regimen. These data suggest that further evaluation of omadacycline for the treatment of MAC-PD is warranted.

Schlagwörter

Stichwörter der Autor:innen

Mycobacterium aviumaerosol infectionanimal modelantibioticnon-tuberculous mycobacteriaomadacyclinetetracycline

Autor:innen und Institutionen

  • AGIR EA4294, Université de Picardie Jules Verne, Amiens, France.
  • Infectious Diseases Department, Amiens-Picardie University Hospital, Amiens, France.
  • Pneumology Department, Amiens-Picardie University Hospital, Amiens, France.
  • Paratek Pharmaceuticals, Inc., King of Prussia, PA, United States.
  • Pathology Department, Amiens-Picardie University Hospital, Amiens, France.

Zitieren

APA

Lanoix, J. P., Froment, A., Delomez, J., Pierce, J. V., Serio, A. W., Choquet, M., Perret, M., Peltier, F., Joseph, C., Chatelain, D., & Andréjak, C. (2026). Efficacy of drug regimens containing omadacycline in a murine model of Mycobacterium avium chronic lung infection. Frontiers in Microbiology, 17. https://doi.org/10.3389/fmicb.2026.1821617

Vancouver

Lanoix JP, Froment A, Delomez J, Pierce JV, Serio AW, Choquet M, et al. Efficacy of drug regimens containing omadacycline in a murine model of Mycobacterium avium chronic lung infection. Frontiers in Microbiology. 2026;17. doi:10.3389/fmicb.2026.1821617

BibTeX
@article{Lanoix2026,
  author = {Lanoix, Jean-Philippe and Froment, Antoine and Delomez, Julia and Pierce, Jessica V and Serio, Alisa W and Choquet, Morgane and Perret, Marie and Peltier, François and Joseph, Cédric and Chatelain, Denis and Andréjak, Claire},
  title = {Efficacy of drug regimens containing omadacycline in a murine model of Mycobacterium avium chronic lung infection},
  journal = {Frontiers in Microbiology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fmicb.2026.1821617}
}
Kostenlos starten →